ArticleThe Journal of clinical endocrinology and metabolism2025
Adverse Cardiometabolic Outcomes in Men With Sisters With Polycystic Ovary Syndrome.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- MASLD, diabetes and PMOS across the female life stages.Diabetologia · 2026Review
- Polyendocrine metabolic ovarian syndrome in pregnancy: pathophysiology and outcomes.Nature reviews. Endocrinology · 2026Review
- Exploring the comorbidity of type 2 diabetes mellitus and polycystic ovary syndrome: treatment with traditional Chinese medicine.Frontiers in medicine · 2026Review
- Adverse Cardiometabolic Outcomes in Men With Sisters With Polycystic Ovary Syndrome.The Journal of clinical endocrinology and metabolism · 2025Article
- Predictive value of serum sortilin, HMGB1, and galanin-like peptide for gestational diabetes mellitus in women with polycystic ovary syndrome.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsSmaller clinical studies report risks of cardiometabolic dysfunction in brothers of women with polycystic ovary syndrome (PCOS). We aim to investigate the risk of adverse cardiometabolic outcomes in men with a sister with PCOS in a large longitudinal population-based cohort.
methodsMen born in Sweden (1973-2013) with ≥1 sister were followed from age 5 until 31 December 2018 (n = 1 098 203) and potential PCOS diagnoses in sisters identified. Risk of a clinical diagnosis of obesity, type 2 diabetes, or hypertension was estimated using Cox regression. In a subcohort, the association between categories of body mass index and blood pressure measured at age 18 to 20 years were estimated using logistic regression. Analyses were adjusted for birth year and parental education.
resultsMen with a sister with PCOS had an increased risk of obesity [adjusted hazard ratio (aHR): 2.02; 95% confidence interval (CI) 1.85-2.21], type 2 diabetes (aHR: 1.62; 95% CI: 1.34-1.96), and hypertension (aHR: 1.24; 95% CI: 1.08-1.43), compared to men with unaffected sisters. In the subcohort evaluated at age 18 to 20 (n = 147 802), having a sister with PCOS (n = 2970) was associated with being overweight [adjusted odds ratio (aOR): 1.33; 95% CI: 1.19-1.49] and obese (aOR: 1.78; 95% CI: 1.47-2.15) but not elevated blood pressure.
conclusionHaving a sister with PCOS is associated with adverse cardiometabolic outcomes in men, already in early adulthood. Results contribute further knowledge on the familial impact of PCOS and highlight a patient group who may benefit from early screening and prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.